A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent‐induced HS

2020 ◽  
Vol 33 (6) ◽  
Author(s):  
Syahrul Sazliyana Shaharir ◽  
Adawiyah Jamil ◽  
Siew Houy Chua ◽  
Mohan Arumugam ◽  
Nurwahyuna Rosli
Keyword(s):  
Literature Review ◽  
Hidradenitis Suppurativa ◽  
Kinase Inhibitor ◽  
Pooled Analysis ◽  
Biological Agent ◽  
Janus Kinase ◽  
Janus Kinase Inhibitor

Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review

Rheumatology ◽  
2020 ◽  
Author(s):  
Zhongxun Yu ◽  
Lin Wang ◽  
Meiying Quan ◽  
Tiannan Zhang ◽  
Hongmei Song
Keyword(s):  
Pilot Study ◽  
Literature Review ◽  
Kinase Inhibitor ◽  
Immunosuppressive Agents ◽  
Janus Kinase ◽  
Muscle Disease ◽  
High Dose ◽  
Type I ◽  
Janus Kinase Inhibitor ◽  
Muscle Testing

Abstract Objectives JDM is a rare autoimmune inflammatory muscle disease with a pronounced IFN signature. Treatment for children with JDM has improved over the years with the use of steroids and immunosuppressive agents. However, there remains a subset of children who have refractory disease. Janus kinase and type I IFN signalling production are suspected to contribute to the pathogenesis of JDM. Our pilot study investigated the use of tofacitinib, a Janus kinase inhibitor, in refractory JDM cases to provide new therapeutic options for better treatment. Methods Refractory JDM was defined as patients who failed two or more steroid sparing agents or high-dose steroids. Tofacitinib was given to three refractory JDM patients with a dose of 5 mg twice per day for at least 6 months. Core set measures defined by Pediatric Rheumatology International Trials Organization were evaluated at month 0, 3 and 6 along with other systemic evaluations. A literature review was conducted to identify all the cases using Janus kinase inhibitors in JDM. Results All three subjects tolerated and responded well to tofacitinib with significant improvement in Child Myositis Assessment Scale, manual muscle testing-8, physician global disease activity and inflammatory indices without occurrence of severe adverse events. Conclusion This pilot study showed improvement of muscle strength, resolution of cutaneous lesions, increased daily quality of life and successful tapering of steroids when tofacitinib used in selected cases. Tofacitinib can be considered with caution when treating refractory JDM cases. Further randomized controlled trials are warranted to assess its efficacy in JDM.

scholarly journals Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

2019 ◽  
Vol 47 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Hidemi Nakagawa ◽  
Osamu Nemoto ◽  
Atsuyuki Igarashi ◽  
Hidehisa Saeki ◽  
Ryusei Murata ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Adult Patients ◽  
Janus Kinase Inhibitor ◽  
Safety And Efficacy

scholarly journals Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters

Xenobiotica ◽  
2021 ◽  
pp. 1-12
Author(s):  
Arnaud Bruyère ◽  
Marc Le Vée ◽  
Elodie Jouan ◽  
Stephanie Molez ◽  
Anne T. Nies ◽  
...  
Keyword(s):  
Kinase Inhibitor ◽  
Drug Transporters ◽  
Janus Kinase ◽  
Janus Kinase Inhibitor ◽  
In Vitro Interactions

scholarly journals Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient

2021 ◽  
pp. 190-194
Author(s):  
Sineida Berbert Ferreira ◽  
Rachel Berbert Ferreira ◽  
Afonso Cesar Neves Neto ◽  
Silvana Martins Caparroz Assef ◽  
Morton Scheinberg
Keyword(s):  
Case Report ◽  
Skin Disease ◽  
Kinase Inhibitor ◽  
Effective Therapy ◽  
Janus Kinase ◽  
Jak Inhibitor ◽  
Adolescent Patient ◽  
Jak Inhibitors ◽  
Janus Kinase Inhibitor ◽  
History Of

Vitiligo is an autoimmune skin disease presenting with areas of depigmentation. Recent reports suggest that Janus kinase (JAK) inhibitors may be an effective therapy. In this case report, we show our experience with an adolescent patient with a long history of generalized and refractory vitiligo, for which treatment with topical tofacitinib, a JAK inhibitor, associated with phototherapy for 9 months, resulted in near complete repigmentation.

Sign in / Sign up

Export Citation Format

Share Document